Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,412 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Process-based therapy Clear all
Terminated Phase 2 Interventional Results available

Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism

NCT00668564
View directory record Official record
Conditions
Hurler's Syndrome, Maroteaux-Lamy Syndrome, Sly Syndrome, Alpha Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Sphingolipidoses, Krabbe Disease, Wolman's Disease, Niemann-Pick Disease Type B, Niemann-Pick Disease, Type C
Interventions
Stem Cell Transplantation, Cyclophosphamide, Campath-1H, Busulfan
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

NCT00003270
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, filgrastim, busulfan, cyclophosphamide, cyclosporine, methylprednisolone, bone marrow ablation with stem cell support, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
5 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

NCT01700946
View directory record Official record
Conditions
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma
Interventions
dexamethasone, vincristine sulfate, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, teniposide, vinblastine, natural killer cell infusion, laboratory biomarker analysis, therapeutic hydrocortisone, allogeneic hematopoietic stem cell transplantation, CliniMACS
Drug · Biological · Other + 2 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
3
States / cities
San Diego, California • Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

NCT03786783
View directory record Official record
Conditions
Ganglioneuroblastoma, High Risk Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Dexrazoxane, Dinutuximab, Doxorubicin, Etoposide, External Beam Radiation Therapy, Isotretinoin, Melphalan, Sargramostim, Thiotepa, Topotecan, Vincristine
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 22, 2026, 5:58 AM EDT
Recruiting Phase 3 Interventional

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

NCT06022939
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Cyclophosphamide, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Echocardiography, Magnetic Resonance Imaging, Melphalan, Positron Emission Tomography, Stem Cell Isolation, Survey Administration
Procedure · Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
117
States / cities
Goodyear, Arizona • Tucson, Arizona • Duarte, California + 93 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 22, 2026, 5:58 AM EDT
Active, not recruiting Phase 1 Interventional

The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.

NCT05010200
View directory record Official record
Conditions
Prostate Cancer
Interventions
PGV-001, Poly-ICLC, CDX-301
Biological
Lead sponsor
Ashutosh Kumar Tewari
Other
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 22, 2026, 5:58 AM EDT
Suspended Phase 1 Interventional

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

NCT02333162
View directory record Official record
Conditions
Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hematologic Malignancy
Interventions
Fludarabine Phosphate, Melphalan, Intensity-Modulated Radiation Therapy, Total Marrow Irradiation, Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Tacrolimus, Mycophenolate Mofetil, Laboratory Biomarker Analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

NCT00003661
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neuroblastoma
Interventions
anti-thymocyte globulin, busulfan, cyclosporine, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 54 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
17
States / cities
Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

NCT00397813
View directory record Official record
Conditions
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Polycythemia Vera, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions
Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
Drug · Other · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
3
States / cities
Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas

NCT00001566
View directory record Official record
Conditions
Ewing's Sarcoma, Rhabdomyosarcoma
Interventions
therapeutic autologous dendritic cells, indinavir sulfate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 35 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2012 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

NCT00003927
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, amifostine trihydrate, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 59 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2023
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 22, 2026, 5:58 AM EDT
Recruiting Not applicable Interventional

Type I Hybrid Effectiveness-Implementation Trial of Primary Care Brief Mindfulness Training for Veterans

NCT06162741
View directory record Official record
Conditions
Post Traumatic Stress Disorder (PTSD), Depression, Anxiety
Interventions
Primary Care Brief Mindfulness Training (PCBMT), Moving Forward (MF)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • San Diego, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Reiki, Yoga, Meditation, on the Physical and Psychological Symptoms of Chemotherapy-Induced Peripheral Neuropathy

NCT01569269
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
Yoga Intervention, Meditation Intervention, Reiki, Holistic Education
Behavioral · Other
Lead sponsor
George Mason University
Other
Eligibility
18 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Oct 22, 2026, 5:58 AM EDT
Completed No phase listed Observational

Medical Therapy Versus Sinus Surgery for Chronic Rhinosinusitis: A Prospective, Multi-institutional Study

NCT01255566
View directory record Official record
Conditions
Chronic Rhinosinusitis, Sinusitis
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Not applicable Interventional Results available

Transcranial Direct Stimulation (tDCS) and Behavioral Intervention in Aphasia

NCT02226796
View directory record Official record
Conditions
Aphasia
Interventions
Transcranial direct current stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
20 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 22, 2026, 5:58 AM EDT
Terminated Phase 1 Interventional

Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus

NCT00325741
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Hematopoietic Cell Transplantation
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 64 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 22, 2026, 5:58 AM EDT
Recruiting Phase 2 Interventional

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

NCT06378866
View directory record Official record
Conditions
Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer, Biochemically Recurrent Prostate Carcinoma
Interventions
Abiraterone, Apalutamide, Biospecimen Collection, Bone Scan, Computed Tomography, Darolutamide, Degarelix, Enzalutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Prednisone, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Radiation Therapy, Image-Guided Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

NCT00588094
View directory record Official record
Conditions
Lymphoma, B-cell Non-Hodgkin's Lymphoma
Interventions
Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 72 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 22, 2026, 5:58 AM EDT
Not listed Phase 1Phase 2 Interventional

Gene Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma

NCT00003942
View directory record Official record
Conditions
Lymphoma
Interventions
RevM10 gene, RevM10/polAS gene, in vitro-treated peripheral blood stem cell transplantation, peripheral blood stem cell transplantation
Biological · Procedure
Lead sponsor
Systemix
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Comparison of Two Approaches to Developing Brain Health Programs

NCT04822129
View directory record Official record
Conditions
Older Persons Interested in Improving Their Brain Health
Interventions
Treatment as Usual, Cogtrastim Model
Behavioral
Lead sponsor
Nova Southeastern University
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

NCT00651937
View directory record Official record
Conditions
Multiple Myeloma, Primary Amyloidosis
Interventions
Melphalan, Stem Cell Infusion, Questionnaires, Granulocyte-colony stimulating factor (G-CSF), Apheresis
Drug · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 22, 2026, 5:58 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Investigating the Efficacy of OMT to Recover Olfactory Perception After COVID-19

NCT06766279
View directory record Official record
Conditions
Anosmia
Interventions
Osteopathic Manipulative Treatment, Sham treatment
Procedure
Lead sponsor
Burrell College of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Las Cruces, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 22, 2026, 5:58 AM EDT
Completed Not applicable Interventional

Congestive Heart Failure Pilot Study Utilizing Wireless Home Scale and Daily Symptom Monitoring

NCT03234088
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Daily weight measured by digital scale and symptom reporting
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 22, 2026, 5:58 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)

NCT00096460
View directory record Official record
Conditions
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Follicular Lymphoma
Interventions
Cyclophosphamide and Rituximab, Filgrastim, Chemotherapy or Radiation therapy, Non-myeloablative Conditioning regimen, Allogeneic transplant, Autologous transplant, Rituximab maintenance therapy, GVHD Prophylaxis
Drug · Radiation · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
30
States / cities
Duarte, California • La Jolla, California • Stanford, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 22, 2026, 5:58 AM EDT